Skip to content

Effects of Gastric Acid on Colonic Microbiome

The Effects of Gastric Acid Suppression on the Colonic Microbiome

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01901276
Enrollment
14
Registered
2013-07-17
Start date
2013-08-31
Completion date
2015-03-31
Last updated
2024-08-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Clostridium Difficile

Keywords

Proton Pump Inhibitors, Microbiome, Clostridium difficile

Brief summary

The colonic microbiome is essential in human health and disease. Clostridium difficile-associated diarrhea (CDAD), a highly morbid form of infectious diarrhea, is caused by antibiotics which perturb the microbiome and allow C. difficile to proliferate. Proton pump inhibitors (PPIs) are powerful suppressors of gastric acid and among the most common medicines in the United States. Dozens of observational studies show that longterm PPI use is associated with CDAD. However, the mechanism by which PPIs cause CDAD is unknown. We believe that PPIs cause CDAD by inducing alterations in the human colonic microbiome. We will confirm or refute the hypothesized mechanism for the association between PPIs and CDAD using an unblinded, single-armed study design. We will use pyrosequencing of the hypervariable V4 region of the bacterial 16S ribosomal subunit gene in human fecal samples to describe the colonic flora. We will collect fecal samples from volunteers before and after PPIs given for different durations and test the microbiome to determine 1) whether PPIs diminish overall diversity, 2) whether PPIs diminish relative abundance of Bacteroidetes, 3) whether increased duration of PPIs affects diversity, and 4) whether there is recovery of diversity after completing a defined course of PPIs. We believe that PPIs will cause a pattern of diminished overall microbiome diversity and reduced anaerobes - the same pattern seen after use of antibiotics. Furthermore, we believe that increased PPI duration will further diminish diversity and that the microbiome will return to pre-PPI levels of diversity after PPIs are stopped. These results will facilitate biologically-based clinical interventions to reduce rates of CDAD among patients who require acid suppression.

Detailed description

Study Design We will recruit 12 adult volunteers for a crossover study with a total duration of 12 weeks. Subjects will be observed off of PPIs for 4 weeks and then will be placed on PPIs for 4 weeks. Subsequently, subjects will be randomized to receive an additional 4 weeks of PPIs or no therapy. Stool samples will be collected at 4 separate time points. Study Outcomes and Statistical Analyses The primary outcome will be change in overall diversity of fecal flora after 4 weeks of PPIs compared to 4 weeks of no acid suppression. Additional outcomes to be assessed include the effect of PPIs on the relative abundance of Bacteroidetes at week 4 and change in the diversity of fecal flora at week 8.

Interventions

DRUGOmeprazole 40 mg bid

As above.

Sponsors

Daniel Freedberg, MD
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* 18 or more years old * Able to give informed consent

Exclusion criteria

* Use of systemic antibiotics within the past year * Use of acid suppression medications (PPIs or H2-receptor antagonists) within the past year (antacids permitted if more than one month from date of enrollment) * History of chronic gastrointestinal mucosal disease (e.g. inflammatory bowel disease, celiac disease, microscopic colitis) * Any clinically significant or uncontrolled major morbidity, including but not limited to serious cardiac or respiratory disease or uncontrolled HIV * Abnormal bowel frequency (minimum once every 2 days, maximum 3 times per day) * Use of clopidogrel or medications with potential significant interaction with PPIs * Osteoperosis or history of non-traumatic bone fracture * History of adverse reactions to PPIs * Initiation of any new medication within the month prior to enrollment * Pregnancy * Inability to give informed consent

Design outcomes

Primary

MeasureTime frameDescription
Shannon Diversity Index Measuring Change in Microbiome DiversityBaseline (Week 0), Week 4, Week 8In order to assess the diversity of the colonic microbiome, the Shannon diversity index will be calculated for each subject: * After four weeks of no acid suppression (Week 0 vs. Week 4) * After four weeks of twice daily PPI (Week 4 vs. Week 8) The Shannon diversity index is a mathematical measure of species diversity in a given community. The Shannon index is calculated as: -∑\[(pi)×ln(pi)\] where H is the Shannon diversity index, and pi is the proportion of individuals of i-th species in a whole community. The minimum value of the Shannon diversity index is 0, which indicates there's no diversity - only one species is found in that habitat. There is no upper limit to the Shannon index. The higher the value of H, the higher the diversity of species in a particular community.

Countries

United States

Participant flow

Participants by arm

ArmCount
Omeprazole 40 mg Bid x 4-8 Weeks
See study description for further details. Omeprazole 40 mg bid: As above.
12
Total12

Withdrawals & dropouts

PeriodReasonFG000FG001
No PPI: Week 0 to Week 4Withdrawal by Subject02

Baseline characteristics

CharacteristicOmeprazole 40 mg Bid x 4-8 Weeks
Age, Continuous40 years
STANDARD_DEVIATION 11
Region of Enrollment
United States
12 participants
Sex: Female, Male
Female
3 Participants
Sex: Female, Male
Male
9 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
0 / 12
other
Total, other adverse events
0 / 12
serious
Total, serious adverse events
0 / 12

Outcome results

Primary

Shannon Diversity Index Measuring Change in Microbiome Diversity

In order to assess the diversity of the colonic microbiome, the Shannon diversity index will be calculated for each subject: * After four weeks of no acid suppression (Week 0 vs. Week 4) * After four weeks of twice daily PPI (Week 4 vs. Week 8) The Shannon diversity index is a mathematical measure of species diversity in a given community. The Shannon index is calculated as: -∑\[(pi)×ln(pi)\] where H is the Shannon diversity index, and pi is the proportion of individuals of i-th species in a whole community. The minimum value of the Shannon diversity index is 0, which indicates there's no diversity - only one species is found in that habitat. There is no upper limit to the Shannon index. The higher the value of H, the higher the diversity of species in a particular community.

Time frame: Baseline (Week 0), Week 4, Week 8

ArmMeasureGroupValue (MEDIAN)
Omeprazole 40 mg Bid x 4-8 WeeksShannon Diversity Index Measuring Change in Microbiome DiversityChange in Shannon indices from Baseline to Week 4 (no PPIs)0.18 Shannon index
Omeprazole 40 mg Bid x 4-8 WeeksShannon Diversity Index Measuring Change in Microbiome DiversityChange in Shannon indices from Week 4 to Week 8 (on PPIs)0.14 Shannon index
Comparison: Within-individual differences in Shannon indices were tested using paired t tests (normally distributed data).p-value: 0.71t-test, 2 sided

Source: ClinicalTrials.gov · Data processed: Mar 17, 2026